vimarsana.com
Home
Live Updates
IV Iron Shows Only Modest Benefit in HF: HEART-FID : comparemela.com
IV Iron Shows Only Modest Benefit in HF: HEART-FID
The largest ever study of IV iron supplementation in patients with heart failure failed to meet a new rigorous definition of significance, and the results were generally regarded as disappointing.
Related Keywords
Duke University ,
North Carolina ,
United States ,
Amsterdam ,
Noord Holland ,
Netherlands ,
United Kingdom ,
Genk ,
Region Flamande ,
Belgium ,
Massachusetts ,
Hasselt ,
Poland ,
Boston ,
American ,
Vifor Pharma ,
John Mcmurray ,
Wilfried Mullens ,
Piotr Ponikowski ,
Pieter Martens ,
Scott Solomon ,
Robertj Mentz ,
Astrazeneca ,
Boehringer Ingelheim ,
Drug Administration ,
Radcliffe Group ,
European Society Of Cardiology ,
Pfizer ,
Daiichi Sankyo Group ,
Duke University School Of Medicine ,
York Heart Association ,
Hasselt University ,
University Of Glasgow ,
University Wroclaw ,
Novartis ,
European Society ,
New England Journal ,
European Heart ,
Duke University School ,
Argue That We Are Not ,
New York Heart Association ,
Ziekenhuis Oost Limburg ,
Medical University Wroclaw ,
Meta Analysis Main Results ,
American Regent ,
Presented August ,
Eur Heart ,
Heart Failure ,
Iron Replacement Therapy ,
Iron Deficiency Anemia ,
Heart ,
Cardiovascular Imaging ,
Ardiac Imaging ,
V Imaging ,
Meta Analysis ,
Intravenous Iv ,
Intravenous ,
Tv ,
Ejection Fraction Ef ,
Eft Ventricular Ejection Fraction Lvef ,
comparemela.com © 2020. All Rights Reserved.